PURPOSE: Our recent study revealed that CD55-high population in breast cancer cell line was resistant to apoptosis and formed colonies in vitro more efficiently than CD55-low population. The present study was conducted to examine whether CD55-high population in breast cancer cell line possesses higher tumorigenic potential in vivo and presence of CD55-high cells in breast cancer affects clinicopathologic behavior of patients. EXPERIMENTAL DESIGN: CD55-high and CD55-low population was sorted from breast cancer cell line, injected into immunodeficient mice, and the resultant tumor volume was measured. CD55 expression was immunohistochemically examined in clinical samples from 74 cases with breast cancers, and cases with >1% of tumor cells showing high level of CD55 expression were categorized as CD55 high. RESULTS: The xenotransplanted tumor volume derived from CD55-high population was significantly larger than that from CD55-low population. Fifty (67.6%) of 74 cases of breast cancer were CD55-high. A significant correlation was observed between CD55-high character and relapse rate (P < 0.001). Univariate analysis showed that tumor size (P = 0.005) and CD55 expression (P = 0.005) were unfavorable prognostic factors. Multivariate analysis revealed that the tumor size (P = 0.013) and CD55 expression (P = 0.011) were independent prognostic factors. CONCLUSIONS: CD55 play an important role in tumorigenesis of breast cancer, and presence of small population of cells with strong CD55 expression would be sufficient to predict poor prognosis of patients.
PURPOSE: Our recent study revealed that CD55-high population in breast cancer cell line was resistant to apoptosis and formed colonies in vitro more efficiently than CD55-low population. The present study was conducted to examine whether CD55-high population in breast cancer cell line possesses higher tumorigenic potential in vivo and presence of CD55-high cells in breast cancer affects clinicopathologic behavior of patients. EXPERIMENTAL DESIGN:CD55-high and CD55-low population was sorted from breast cancer cell line, injected into immunodeficient mice, and the resultant tumor volume was measured. CD55 expression was immunohistochemically examined in clinical samples from 74 cases with breast cancers, and cases with >1% of tumor cells showing high level of CD55 expression were categorized as CD55 high. RESULTS: The xenotransplanted tumor volume derived from CD55-high population was significantly larger than that from CD55-low population. Fifty (67.6%) of 74 cases of breast cancer were CD55-high. A significant correlation was observed between CD55-high character and relapse rate (P < 0.001). Univariate analysis showed that tumor size (P = 0.005) and CD55 expression (P = 0.005) were unfavorable prognostic factors. Multivariate analysis revealed that the tumor size (P = 0.013) and CD55 expression (P = 0.011) were independent prognostic factors. CONCLUSIONS:CD55 play an important role in tumorigenesis of breast cancer, and presence of small population of cells with strong CD55 expression would be sufficient to predict poor prognosis of patients.
Authors: Budhaditya Mazumdar; Hangeun Kim; Keith Meyer; Sandip K Bose; Adrian M Di Bisceglie; Ratna B Ray; Michael S Diamond; John P Atkinson; Ranjit Ray Journal: J Virol Date: 2013-05-08 Impact factor: 5.103
Authors: Arthur T Kopylov; Alexander A Stepanov; Kristina A Malsagova; Deepesh Soni; Nikolay E Kushlinsky; Dmitry V Enikeev; Natalia V Potoldykova; Andrey V Lisitsa; Anna L Kaysheva Journal: Molecules Date: 2020-01-31 Impact factor: 4.411
Authors: Bridget Charbonneau; Matthew J Maurer; Zachary S Fredericksen; Clive S Zent; Brian K Link; Anne J Novak; Stephen M Ansell; George J Weiner; Alice H Wang; Thomas E Witzig; Ahmet Dogan; Susan L Slager; Thomas M Habermann; James R Cerhan Journal: Am J Hematol Date: 2012-06-20 Impact factor: 10.047
Authors: Katharina Theresa Kohler; Nadine Goldhammer; Samuel Demharter; Ulrich Pfisterer; Konstantin Khodosevich; Lone Rønnov-Jessen; Ole William Petersen; René Villadsen; Jiyoung Kim Journal: NPJ Breast Cancer Date: 2022-07-12
Authors: Anne Monks; Yingdong Zhao; Curtis Hose; Hossein Hamed; Julia Krushkal; Jianwen Fang; Dmitriy Sonkin; Alida Palmisano; Eric C Polley; Laura K Fogli; Mariam M Konaté; Sarah B Miller; Melanie A Simpson; Andrea Regier Voth; Ming-Chung Li; Erik Harris; Xiaolin Wu; John W Connelly; Annamaria Rapisarda; Beverly A Teicher; Richard Simon; James H Doroshow Journal: Cancer Res Date: 2018-10-24 Impact factor: 12.701
Authors: Felicia Leccia; Luigi Del Vecchio; Elisabetta Mariotti; Rosa Di Noto; Anne-Pierre Morel; Alain Puisieux; Francesco Salvatore; Stéphane Ansieau Journal: Mol Cancer Date: 2014-09-12 Impact factor: 27.401
Authors: F Cimmino; M Avitabile; L Pezone; G Scalia; D Montanaro; M Andreozzi; L Terracciano; A Iolascon; M Capasso Journal: Oncogenesis Date: 2016-04-04 Impact factor: 7.485